Complete reference for 10 cannabinoids found in cannabis, including their effects, medical applications, and how they interact with the body.
CBC
Psychoactive: Yes
Cannabichromene (CBC) is a non-psychoactive cannabinoid with unique neurological and pain-relieving properties that distinguish it from other cannabis compounds. CBC works by inhibiting the reuptake of anandamide (often called the 'bliss molecule'), allowing this natural endocannabinoid to remain active longer in the body's system, thereby enhancing mood regulation, pain relief, and overall homeostasis. One of CBC's most remarkable properties is its ability to promote neurogenesis - the growth of new brain cells - particularly in the hippocampus, the brain region responsible for memory formation and learning. This neurogenic potential has sparked intense research interest in CBC's applications for neurodegenerative diseases, depression, and cognitive enhancement. Recent 2024 studies have revealed CBC's significant effectiveness against neuropathic pain through its activation of TRPV1 (vanilloid) and TRPA1 (ankyrin) receptors, providing pain relief through mechanisms different from traditional analgesics. CBC also demonstrates potent anti-inflammatory and antibacterial properties, showing effectiveness against both gram-positive and gram-negative bacteria. When combined with other cannabinoids (particularly THC and CBD), CBC exhibits strong entourage effects, enhancing the overall therapeutic potential of cannabis-based treatments while maintaining its non-intoxicating profile.
CBD
Psychoactive: Yes
Cannabidiol (CBD) is the most extensively researched non-psychoactive cannabinoid, offering therapeutic benefits without the intoxicating effects associated with THC. Unlike THC, CBD does not directly bind to CB1 or CB2 receptors but instead modulates the endocannabinoid system indirectly, enhancing the body's natural production of endocannabinoids like anandamide. CBD's therapeutic mechanisms involve interaction with serotonin 5-HT1A receptors (providing anxiolytic effects), vanilloid TRPV1 receptors (pain and inflammation control), and GPR55 receptors (bone health and blood pressure regulation). The FDA approved CBD as Epidiolex in 2018 for treatment-resistant childhood epilepsy syndromes (Dravet and Lennox-Gastaut), marking the first plant-derived cannabinoid medication approved in the United States. Extensive clinical research demonstrates CBD's efficacy in reducing anxiety disorders, chronic pain, and inflammation, while ongoing studies investigate its neuroprotective properties for conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. CBD's excellent safety profile and lack of addiction potential make it an attractive alternative to traditional pharmaceuticals for many patients seeking natural therapeutic options.
CBDA
Psychoactive: Yes
Cannabidiolic acid (CBDA) is the acidic precursor to CBD found abundantly in raw cannabis and hemp plants, converting to CBD through decarboxylation when exposed to heat or light. While historically overshadowed by CBD, CBDA demonstrates unique therapeutic properties with superior bioavailability and faster-acting effects compared to its decarboxylated form. Research from GW Pharmaceuticals reveals CBDA is 1,000 times more potent than CBD at activating 5-HT1A serotonin receptors, making it exceptionally effective for nausea and vomiting, particularly anticipatory nausea associated with chemotherapy—a condition with no established pharmaceutical treatment. CBDA functions as a COX-2 enzyme inhibitor similar to NSAIDs like ibuprofen, providing anti-inflammatory benefits through mechanisms comparable to traditional pain medications. GW Pharmaceuticals research mandated by the FDA demonstrates CBDA may be more effective than CBD for seizure control, with dose-dependent protection shown in animal seizure models, leading to medical-use patents for epilepsy treatment. A 2023 study published in PMC demonstrated CBDA and THCA reduced hippocampal amyloid-beta and phosphorylated tau proteins in Alzheimer's disease mouse models while improving cognitive function and memory. An open-label human trial for Restless Leg Syndrome using topical magnesium-coordinated CBDA showed statistically significant improvements in sleep disturbances with no adverse effects. Preclinical research suggests CBDA exhibits anti-cancer properties by inhibiting migration of aggressive breast cancer cells, anxiolytic effects at extremely low doses in animal studies, and neuroprotective benefits. However, CBDA's chemical instability presents challenges, as it naturally degrades to CBD with heat, light, or time, requiring specialized formulations like magnesium-coordinated CBDA or synthetic derivatives for therapeutic stability. While preclinical evidence is compelling, large-scale human clinical trials remain limited, and no FDA-approved CBDA products currently exist for medical use.
CBDV
Psychoactive: Yes
Cannabidivarin (CBDV) is a non-intoxicating cannabinoid structurally similar to CBD, featuring a propyl side chain instead of CBD's pentyl chain. First isolated in 1969, CBDV is under investigation for neurological conditions and inflammatory disorders, though clinical evidence remains limited compared to CBD. CBDV exerts its effects primarily through modulation of TRP channels (TRPV1, TRPV2, TRPA1, TRPM8) rather than direct CB1/CB2 receptor binding, making it completely non-psychoactive. A 2021 Phase 2 clinical trial (NCT02365610) testing 1,600mg daily for focal epilepsy in adults failed to meet its primary endpoint, showing no significant difference versus placebo despite good safety and tolerability. However, a small 2022 Phase 1 trial published in Epilepsia showed promising preliminary results in five children with Rett syndrome and drug-resistant epilepsy, achieving a 79% median reduction in seizure frequency at 10mg/kg/day dosing, though larger trials are needed for confirmation. Preclinical research in animal models demonstrates CBDV may reduce autism-like behaviors and affect glutamate levels in the brain, and GW Pharmaceuticals continues developing CBDV-based medications for epilepsy and Prader-Willi syndrome. CBDV's anti-inflammatory mechanism works by blocking TLR4 signaling and reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in laboratory studies. Animal research suggests CBDV may enhance morphine's analgesic effects and exhibits anti-nausea properties. CBDV occurs naturally in trace amounts (0.1-0.2%) in most cannabis strains, with higher concentrations in certain landrace indica strains and CBD-rich varieties. Specially bred strains now achieve 4-6% CBDV concentrations. While early research is encouraging, CBDV lacks the robust clinical evidence supporting FDA-approved cannabinoids like CBD (Epidiolex), and most therapeutic claims remain based on preclinical data requiring human validation.
CBG
Psychoactive: Yes
Cannabigerol (CBG) is rightfully called the 'mother of all cannabinoids' because it serves as the precursor molecule from which all other cannabinoids are synthesized in the cannabis plant through enzymatic conversion. Young cannabis plants contain high levels of CBGA (cannabigerolic acid), which is then converted into THCA, CBDA, and CBCA as the plant matures, leaving mature plants with typically low CBG concentrations (usually less than 1%). CBG interacts with both CB1 and CB2 receptors but with relatively low affinity, instead exerting its therapeutic effects through alpha-2 adrenergic receptors, 5-HT1A serotonin receptors, and TRPV1 vanilloid receptors. Recent 2024 research has confirmed CBG's remarkably potent antibacterial properties, showing effectiveness against antibiotic-resistant bacteria including MRSA, making it a promising candidate for addressing the growing crisis of antibiotic resistance. CBG demonstrates significant neuroprotective benefits for neurodegenerative diseases like Huntington's disease, Parkinson's disease, and multiple sclerosis, reducing neuroinflammation and oxidative stress without causing sedation or cognitive impairment. Unlike many other cannabinoids, CBG actually promotes alertness and focus while simultaneously providing therapeutic benefits, making it particularly valuable for daytime medical use and potentially beneficial for treating attention disorders and depression.
CBGA
Psychoactive: Yes
Cannabigerolic acid (CBGA) is rightfully known as the 'mother of all cannabinoids' because it serves as the biosynthetic precursor from which all major cannabinoids are derived in the cannabis plant. Through enzymatic conversion, CBGA transforms into THCA, CBDA, and CBCA as the plant matures, making it the foundational molecule of cannabinoid biosynthesis. CBGA demonstrates the most potent inhibition of TRPM7 ion channels among all cannabinoids tested, a mechanism relevant for treating conditions including cancer, stroke, and kidney disease. A 2023 study published in the journal Function showed CBGA prevented kidney damage and suppressed inflammatory cytokine expression in acute nephropathic mouse models. Preclinical research published in 2020 found pure CBGA more effective than commercial oral care products in reducing dental plaque bacteria colony counts, demonstrating broad-spectrum antibacterial activity against fungi, gram-positive bacteria including MRSA, gram-negative bacteria, and parasites. CBGA functions as a dual PPARα/γ agonist, potentially treating diabetes and dyslipidemia by stimulating lipid metabolism and reducing fat accumulation, with animal trials showing blood pressure reduction and slowed atherosclerosis progression. However, CBGA exhibits divergent effects on seizures according to a 2021 British Journal of Pharmacology study, showing anticonvulsant properties in some epilepsy models while demonstrating proconvulsant effects at high doses in others, requiring careful consideration for epilepsy applications. Unlike CBD or CBG, CBGA does not strongly bind CB1 or CB2 receptors but instead modulates GPR55 receptors, T-type calcium channels, and TRPM7 channels. CBGA occurs naturally in young cannabis plants but rapidly converts to other cannabinoids during maturation, with some hemp varieties exhibiting enzymatic deficiencies that preserve higher CBGA concentrations. While preclinical research is promising across multiple therapeutic areas including neuroprotection and anti-cancer effects, human clinical trials are minimal, and no FDA-approved CBGA products currently exist. Most therapeutic claims remain based on in vitro and animal model research requiring human validation.
CBN
Psychoactive: Yes
Cannabinol (CBN) is often called the 'sleepy cannabinoid' due to its potent sedative properties, though its formation process is unique among cannabinoids. CBN is not directly produced by the cannabis plant but rather forms through the oxidation and degradation of THC when exposed to heat, light, or air over time, making aged cannabis naturally higher in CBN content. This cannabinoid binds weakly to CB1 receptors but shows strong affinity for CB2 receptors, contributing to its distinctive effects profile that emphasizes relaxation and sleep induction rather than cognitive alteration. Clinical research has demonstrated that CBN produces sedative effects comparable to pharmaceutical sleep aids like diazepam, making it particularly valuable for treating insomnia and sleep disorders. Beyond its sleep-promoting properties, CBN exhibits significant antibacterial activity, with studies showing effectiveness against antibiotic-resistant bacteria including MRSA (methicillin-resistant Staphylococcus aureus). Recent research also suggests CBN may stimulate appetite, reduce inflammation, and provide neuroprotective benefits, though its primary therapeutic application remains focused on sleep enhancement and as a natural alternative to conventional sleep medications for patients seeking non-habit-forming solutions.
THC
Psychoactive: Yes
Δ9-Tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis, responsible for the characteristic 'high' associated with marijuana use. THC exerts its effects by binding to cannabinoid receptors (CB1 and CB2) throughout the body's endocannabinoid system, with CB1 receptors concentrated in the brain and nervous system affecting cognition, memory, motor function, and pain perception. This interaction triggers the release of dopamine in the brain's reward pathways, producing euphoria, relaxation, and altered sensory perception. Medically, THC demonstrates remarkable efficacy for chronic pain management, particularly neuropathic pain conditions that respond poorly to traditional analgesics. The FDA has approved synthetic THC (dronabinol) for appetite stimulation in cancer and HIV/AIDS patients, as well as for chemotherapy-induced nausea and vomiting. Research continues to explore THC's potential in treating PTSD, multiple sclerosis spasticity, and treatment-resistant epilepsy, though its psychoactive properties require careful dosing and medical supervision.
THCA
Psychoactive: Yes
Tetrahydrocannabinolic acid (THCA) is the non-psychoactive precursor to THC found abundantly in raw, fresh cannabis plants before decarboxylation (heating) converts it to psychoactive THC. This transformation explains why consuming raw cannabis doesn't produce intoxicating effects, allowing patients to access THCA's therapeutic benefits without impairment. THCA functions as a potent PPARγ (peroxisome proliferator-activated receptor gamma) agonist, a mechanism that provides significant neuroprotective effects and helps regulate inflammation, metabolism, and cellular energy production. Research has shown THCA's ability to reduce amyloid-beta protein accumulation in the brain, a hallmark of Alzheimer's disease, suggesting potential applications in preventing or slowing neurodegenerative progression. Unlike its decarboxylated counterpart THC, THCA does not bind to CB1 or CB2 receptors, instead exerting its effects through interaction with TRPV channels and COX enzymes, providing anti-inflammatory and antioxidant benefits. THCA demonstrates particular promise in treating autoimmune conditions, seizure disorders, and chronic inflammatory diseases, with many patients incorporating raw cannabis juice or tinctures into their wellness routines. The compound's stability in acidic conditions and degradation when exposed to heat or light requires specific handling and consumption methods to maintain therapeutic potency.
THCV
Psychoactive: Yes
Tetrahydrocannabivarin (THCV) is often dubbed 'diet weed' due to its unique appetite-suppressing properties that directly oppose THC's well-known munchies effect. THCV exhibits a fascinating dose-dependent relationship with the endocannabinoid system: at low doses (under 10mg), it acts as a CB1 receptor antagonist, blocking appetite stimulation and providing clear-headed, energizing effects without psychoactivity; at higher doses (above 10mg), it can produce mild psychoactive effects similar to a shorter, more clear-headed THC experience. This dual mechanism makes THCV particularly valuable for weight management and metabolic health, with 2024 clinical trials demonstrating significant improvements in blood sugar control, glucose tolerance, and insulin sensitivity in type 2 diabetic patients. THCV's molecular structure, containing a 3-carbon side chain instead of THC's 5-carbon chain, allows it to cross the blood-brain barrier efficiently while promoting neurogenesis and providing neuroprotective benefits for conditions like Parkinson's disease and epilepsy. Research indicates THCV may also support bone health by stimulating bone cell growth and preventing bone loss, making it potentially valuable for treating osteoporosis. However, THCV requires higher vaporization temperatures (428°F vs 315°F for THC) to activate, and it's naturally found in higher concentrations in African landrace sativas, making it relatively rare in modern cannabis cultivars.